Palonosetron intravenous - Dr. Reddy

Drug Profile

Palonosetron intravenous - Dr. Reddy

Alternative Names: Palonosetron hydrochloridee intravenous - Dr. Reddy

Latest Information Update: 03 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dr Reddys Laboratories
  • Class Antiemetics; Isoquinolines; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting

Most Recent Events

  • 02 Nov 2012 The US FDA issues tentative approval to palonosetron (0.075 mg/1.5mL and 0.25 mg/5mL) injection for Postoperative nausea and vomiting and Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 03 Jan 2012 Preregistration for Chemotherapy induced nausea and vomiting (Prevention) in USA (IV)
  • 03 Jan 2012 Preregistration for Postoperative nausea and vomiting (Prevention) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top